{"title":"Biomimetic nanocarriers for targeted therapy of colorectal cancer.","authors":"Shivam Pathak, Rupam Bera, Anjana Sharma, Dipti Kakkar, Balak Das Kurmi, Pradhi Srivasatava, Maitrayee Ghosh, Nitin Sharma","doi":"10.1080/17425247.2025.2570847","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer remains one of the most prevalent and lethal malignancies worldwide, with treatment often hampered by poor drug bioavailability, systemic toxicity, and resistance to conventional therapies. Biomimetic nanocarriers have emerged as a promising strategy to overcome these limitations by combining nanotechnology with the biological functions of cell-derived membranes.</p><p><strong>Areas covered: </strong>This review critically examines the design, fabrication, and application of biomimetic nanocarriers specifically for Colorectal cancer. Focusing on various membrane coatings, including red blood cells, platelets and cancer cells, and their role in enhancing drug delivery efficacy. It further explores the application of these nanocarriers in chemotherapy, immunotherapy, gene therapy, photothermal therapy, and cancer theranostics, while also discussing advances in targeting the unique tumor microenvironment of Colorectal cancer.Literature was retrieved from PubMed, Scopus, Web of Science and Google scholar databases covering publications from 2012 to May 2025.</p><p><strong>Expert opinion: </strong>Despite encouraging preclinical results, the clinical translation of biomimetic nanocarriers faces challenges including scalability, membrane heterogeneity, immunogenicity, and regulatory hurdles. Furthermore, existing studies often overlook the unique features of the Colorectal cancer tumor microenvironment. Future research should focus on precision nanomedicine tailored to Colorectal cancer, addressing current limitations to enable safer, more effective, and targeted cancer management.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425247.2025.2570847","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Colorectal cancer remains one of the most prevalent and lethal malignancies worldwide, with treatment often hampered by poor drug bioavailability, systemic toxicity, and resistance to conventional therapies. Biomimetic nanocarriers have emerged as a promising strategy to overcome these limitations by combining nanotechnology with the biological functions of cell-derived membranes.
Areas covered: This review critically examines the design, fabrication, and application of biomimetic nanocarriers specifically for Colorectal cancer. Focusing on various membrane coatings, including red blood cells, platelets and cancer cells, and their role in enhancing drug delivery efficacy. It further explores the application of these nanocarriers in chemotherapy, immunotherapy, gene therapy, photothermal therapy, and cancer theranostics, while also discussing advances in targeting the unique tumor microenvironment of Colorectal cancer.Literature was retrieved from PubMed, Scopus, Web of Science and Google scholar databases covering publications from 2012 to May 2025.
Expert opinion: Despite encouraging preclinical results, the clinical translation of biomimetic nanocarriers faces challenges including scalability, membrane heterogeneity, immunogenicity, and regulatory hurdles. Furthermore, existing studies often overlook the unique features of the Colorectal cancer tumor microenvironment. Future research should focus on precision nanomedicine tailored to Colorectal cancer, addressing current limitations to enable safer, more effective, and targeted cancer management.
导读:结直肠癌仍然是世界范围内最普遍和最致命的恶性肿瘤之一,其治疗往往受到药物生物利用度差、全身毒性和对传统疗法的耐药性的阻碍。仿生纳米载体通过将纳米技术与细胞源性膜的生物学功能相结合,已经成为克服这些限制的一种有前途的策略。涉及领域:本文综述了结直肠癌仿生纳米载体的设计、制造和应用。重点研究各种膜涂层,包括红细胞、血小板和癌细胞,以及它们在提高药物传递效率中的作用。进一步探讨了这些纳米载体在化疗、免疫治疗、基因治疗、光热治疗、癌症治疗等方面的应用,同时探讨了针对结直肠癌独特肿瘤微环境的研究进展。文献检索自PubMed, Scopus, Web of Science和b谷歌学者数据库,涵盖2012年至2025年5月的出版物。专家意见:尽管临床前结果令人鼓舞,但仿生纳米载体的临床转化面临着可扩展性、膜异质性、免疫原性和监管障碍等挑战。此外,现有研究往往忽略了结直肠癌肿瘤微环境的独特性。未来的研究应该集中在为结直肠癌量身定制的精确纳米医学上,解决当前的局限性,使癌症管理更安全、更有效、更有针对性。